Devonian Health Group Reports Second Quarter 2025 Financial Results
Devonian Health Group (OTCQB: DVHGF) reported strong Q2 2025 financial results with revenue soaring 275% year-over-year to $8.28 million, primarily driven by DEXLANSOPRAZOLE distribution agreement. The company posted a net loss of $0.001 per share, improving from $0.01 loss per share in the previous year.
The company's cash position stood at $8.4 million with zero debt, down from $9.9 million at fiscal year start. Notable achievements include Thykamine™'s superior performance in anti-inflammatory studies versus corticosteroids, positive results in MASH mouse model studies, and new provisional patent applications for Thykamine™ in metabolic dysfunction-associated steatohepatitis and as an anti-fibrotic agent.
Devonian Health Group (OTCQB: DVHGF) ha riportato solidi risultati finanziari nel secondo trimestre del 2025 con ricavi in crescita del 275% su base annua, raggiungendo 8,28 milioni di dollari, principalmente grazie all'accordo di distribuzione del DEXLANSOPRAZOLE. L'azienda ha registrato una perdita netta di 0,001 dollari per azione, migliorando rispetto alla perdita di 0,01 dollari per azione dell'anno precedente.
La posizione di cassa dell'azienda si attestava a 8,4 milioni di dollari senza debiti, in calo rispetto ai 9,9 milioni all'inizio dell'anno fiscale. Tra i risultati più rilevanti spiccano le prestazioni superiori di Thykamine™ negli studi anti-infiammatori rispetto ai corticosteroidi, risultati positivi nei test sul modello murino MASH e nuove domande di brevetto provvisorie per Thykamine™ nella steatoepatite associata a disfunzioni metaboliche e come agente anti-fibrotico.
Devonian Health Group (OTCQB: DVHGF) reportó sólidos resultados financieros en el segundo trimestre de 2025 con ingresos que se dispararon un 275% interanual hasta 8,28 millones de dólares, impulsados principalmente por el acuerdo de distribución de DEXLANSOPRAZOLE. La compañía registró una pérdida neta de 0,001 dólares por acción, mejorando desde una pérdida de 0,01 dólares por acción en el año anterior.
La posición de efectivo de la empresa fue de 8,4 millones de dólares sin deuda, disminuyendo desde 9,9 millones al inicio del año fiscal. Entre los logros destacados se encuentran el desempeño superior de Thykamine™ en estudios antiinflamatorios frente a corticosteroides, resultados positivos en estudios con el modelo de ratón MASH y nuevas solicitudes provisionales de patente para Thykamine™ en esteatohepatitis asociada a disfunción metabólica y como agente antifibrótico.
Devonian Health Group (OTCQB: DVHGF)는 2025년 2분기 강력한 재무 실적을 발표했으며, 매출이 전년 대비 275% 증가한 828만 달러에 달했습니다. 이는 주로 DEXLANSOPRAZOLE 유통 계약에 힘입은 결과입니다. 회사는 주당 0.001달러 순손실을 기록했으며, 이는 전년도의 주당 0.01달러 손실에서 개선된 수치입니다.
회사의 현금 보유액은 840만 달러로 부채는 없으며, 회계연도 시작 시점의 990만 달러에서 감소한 수치입니다. 주요 성과로는 Thykamine™이 코르티코스테로이드 대비 항염증 연구에서 우수한 성능을 보인 점, MASH 생쥐 모델 연구에서 긍정적인 결과, 그리고 대사 기능 장애 관련 지방간염 및 항섬유화제로서 Thykamine™에 대한 신규 임시 특허 출원이 포함됩니다.
Devonian Health Group (OTCQB : DVHGF) a annoncé de solides résultats financiers pour le deuxième trimestre 2025 avec un chiffre d'affaires en hausse de 275 % sur un an à 8,28 millions de dollars, principalement grâce à l'accord de distribution du DEXLANSOPRAZOLE. La société a enregistré une perte nette de 0,001 dollar par action, en amélioration par rapport à la perte de 0,01 dollar par action de l'année précédente.
La trésorerie de l'entreprise s'élevait à 8,4 millions de dollars sans dettes, en baisse par rapport à 9,9 millions au début de l'exercice. Parmi les réalisations notables figurent la performance supérieure de Thykamine™ dans des études anti-inflammatoires par rapport aux corticostéroïdes, des résultats positifs dans des études sur le modèle murin MASH, ainsi que de nouvelles demandes de brevets provisoires pour Thykamine™ dans la stéato-hépatite associée à des dysfonctionnements métaboliques et en tant qu'agent anti-fibrotique.
Devonian Health Group (OTCQB: DVHGF) meldete starke Finanzergebnisse für das zweite Quartal 2025 mit einem Umsatzanstieg von 275 % im Jahresvergleich auf 8,28 Millionen US-Dollar, hauptsächlich getrieben durch den Vertriebsvertrag für DEXLANSOPRAZOLE. Das Unternehmen verzeichnete einen Nettoverlust von 0,001 US-Dollar je Aktie, eine Verbesserung gegenüber dem Verlust von 0,01 US-Dollar je Aktie im Vorjahr.
Die Liquiditätsposition des Unternehmens lag bei 8,4 Millionen US-Dollar bei null Schulden, was einem Rückgang von 9,9 Millionen zu Beginn des Geschäftsjahres entspricht. Zu den bemerkenswerten Erfolgen zählen die überlegene Leistung von Thykamine™ in entzündungshemmenden Studien im Vergleich zu Kortikosteroiden, positive Ergebnisse in MASH-Mausmodellen sowie neue vorläufige Patentanmeldungen für Thykamine™ bei stoffwechselbedingter Steatohepatitis und als antifibrotischer Wirkstoff.
- Revenue increased 275% YoY to $8.28 million
- Net loss reduced significantly to $0.001 per share from $0.01
- Eliminated all debt while maintaining $8.4M cash position
- Thykamine™ demonstrated superior anti-inflammatory efficacy in comparative studies
- Filed new provisional patents for Thykamine™ applications
- Cash position decreased from $9.9M to $8.4M
- DEXLANSOPRAZOLE distribution agreement expiring in April 2025, affecting future revenue
- Company still operating at a loss despite improved metrics
-
Second quarter revenue increased
275% year over year -
Second quarter net loss of
$0.00 1 - Debt repaid in full
Management Comments
“Devonian continued to improve its financial position in the second fiscal quarter ended January 31, 2025,” said Luc Gregoire, President and Chief executive Officer of Devonian. “The operating cash flows generated by Altius revenues continued to support the development progress of our lead product candidate Thykamine™ and improve our financial position by erasing all our debt. While the distribution agreement for DEXLANSOPRAZOLE will soon expire, our current liquidity will enable us to continue creating a lot of value from our expected scientific progress over the next year.”
Dr. André Boulet, Chairman, Chief Operating Officer and Chief Scientific Officer added, “The several readouts of our recent studies are clearly establishing Thykamine™ as a potent immunomodulatory agent for the potential treatment of a wide array of autoimmune inflammatory diseases”.
Business Highlights in Second Quarter to Date
- Thykamine™ achieved superior anti-inflammatory potency in a comparative in vitro study against corticosteroids and other first line treatments of inflammatory disease.
- Positive results from the STAM mouse model in vivo study attributing Thykamine™ with anti-MASH and anti-fibrosis effects in liver.
- Filed provisional patent applications for uses of Thykamine™ in metabolic dysfunction-associated steatohepatitis (MASH) and as an anti-fibrotic agent.
- Appointment of Chief Financial Officer - Viktoria Krasteva, CPA, CA
Financial Highlights
-
Distribution revenue for the second quarter was
$8.28 million -
Net loss for the quarter was
$0.22 8 million$0.00 1$1.21 0 million$0.01 -
Cash and cash equivalents on January 31, 2025, was
$8.4 million $9.9 million $2.1 million
To consult the Interim Consolidated Financial Statements for the six month period ended January 31, 2025 and 2024, please click on the following link: https://groupedevonian.com/investor-center/financial-reports/.
About Devonian
Devonian Health Group is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US FDA set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in
Devonian Health Group Inc. was incorporated in 2015 and is headquartered in
For more information, visit www.groupedevonian.com
About Altius
Altius is a generic pharmaceutical distribution division with a primary focus of acquiring and in-licensing safe and innovative medicines and healthcare products designed to help people of all ages live healthier lives. Altius then leverages its expertise in the commercialization activities required to successfully launch and distribute these medicines in
Cautionary Note Regarding Forward-Looking Statements
All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the impact of proposed optimizations at the Company’s projects, global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future conditions, changes in accounting policies, the impact of inflation, the PCT patents for ThykamineTM might not be granted, and, generally, the above “About Devonian” and “About Altius” paragraphs, which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of
Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415758058/en/
Devonian Health Group Inc.
Mr. Luc Grégoire
President and CEO
Dr. André Boulet
Chairman, COO and CSO
Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com
Source: Devonian Health Group Inc.
FAQ
What drove DVHGF's 275% revenue growth in Q2 2025?
How much did DVHGF reduce its net loss per share in Q2 2025?
What are the latest developments for DVHGF's Thykamine™ product?
What is DVHGF's current cash position and debt status as of Q2 2025?
